Finance

Lists
IKT:NASDAQ
Inhibikase Therapeutics Inc
$2.05
-0.19%
(-0.0040) 1D
Oct 1, 9:48:51 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IKT...
Open
$2.10
High
$2.10
Low
$2.03
Mkt. cap
285.49M
Avg. vol.
523.64K
Volume
18.04K
52-wk high
$2.61
52-wk low
$1.33
EPS
-$0.44
Beta
0.95
Shares outstanding
139.54M
No. of employees
35
Open
$2.10
High
$2.10
Low
$2.03
Mkt. cap
285.49M
Avg. vol.
523.64K
Volume
18.04K
52-wk high
$2.61
52-wk low
$1.33
EPS
-$0.44
Beta
0.95
Shares outstanding
139.54M
No. of employees
35
News stories
From web sources and news partners
About Inhibikase Therapeutics Inc
CEO-
Employees35
Founded2008
HeadquartersWilmington, Delaware, United States
SectorBiotechnology
Websiteinhibikase.com
Analyst ratings
Based on 5 analysts giving stock ratings to IKT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for IKT in the last 3 months.
Highest
Current $2.05
$8.00 (+290.05%)
Average
$6.40 (+212.04%)
Lowest
$5.00 (+143.78%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gaurav Maini
LifeSci Capital
Buy
Maintained
$5.00
+143.8%
09/15/2026
Jason McCarthy
Maxim Group
Buy
Maintained
$8.00
+290.1%
08/13/2026
Mazahir Alimohamed
Oppenheimer
Buy
Maintained
$5.00
+143.8%
08/12/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$8.00
+290.1%
07/31/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$6.00
+192.5%
07/27/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$4.00
+95%
05/18/2026
Aydin Huseynov
Ladenburg Thalmann & Co.
Buy
Initiated
$4.00
+95%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
7.65M
-23.43M
-
-
Cost of revenue
7.65M
-23.43M
-
-
Research and development expenses
-
22.39M
10.84M
13.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.61M
6.77M
7.38M
7.66M
Operating expense
5.61M
29.17M
18.22M
21.05M
Total operating expenses
13.26M
5.73M
18.22M
21.05M
Operating income
-13.26M
-5.73M
-18.22M
-21.05M
Other non operating income
-
-
1.46M
1.46M
EBT including unusual items
-11.93M
-12.73M
-16.38M
-19.59M
EBT excluding unusual items
-12.42M
-4.69M
-16.75M
-19.59M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.93M
-12.73M
-16.38M
-19.59M
Net profit margin
-
-
-
-
Earnings per share
-
-
-0.10
-0.11
Interest and investment income
838.09K
1.04M
-
-
Interest expense
-
-
-
-
Net interest expenses
838.09K
1.04M
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.24M
-5.73M
-18.20M
-21.04M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps